Inhibikase Therapeutics Inc. Common Stock (IKT)
Stock · NASDAQ · Health Care
$1.66as of 10/16/2026
Price chart
Active signals
IKT Signal Track Record
How signals performed across all stocks →What IKT's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 43 | +0.6% | 51% | September 18, 2026 |
| Bollinger Band BreakdownActive now | 22 | +6.9% | 59% | September 21, 2026 |
| Bollinger Band Breakout | 17 | -1.6% | 41% | July 20, 2026 |
| 200-Day Moving Average TouchActive now | 13 | -0.6% | 46% | October 1, 2026 |
| Any 20-session window (baseline) | -3.3% | 43% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About IKT
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate design…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 35
- Website
- www.inhibikase.com/
Fundamentals
- 1-day range
- $1.8$1.87
- Market cap
- $318.20M
- P/E (trailing)
- —
- P/E (forward)
- -4.36
- EPS (trailing)
- $-0.50
- Dividend yield
- —
- Beta
- 0.92
- Avg. volume
- 620.9K
How Inhibikase Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2022 annual results
Source: 10-K filed Mar 31, 2023 · via SEC EDGAR / Finnhub
Forecasts
10 analyst ratings
Inhibikase Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- IKTInhibikase Therapeutics Inc. Common Stock$1.65▼ 9.84%Market cap $318.20MP/E —$1.33$2.61
- AVXLAnavex Life Sciences Corp. Common Stock$1.31▼ 11.49%Market cap $303.96MP/E —$1.56$10.38
- NMRANeumora Therapeutics Inc. Common Stock$0.474▲ 11.01%Market cap $303.87MP/E —$0.3154$3.65
- AGENAgenus Inc. Common Stock$6.04▼ 9.58%Market cap $335.19MP/E 3.19$2.71$10.31
- SABSSAB Biotherapeutics Inc. Common Stock$2.53▼ 2.32%Market cap $294.39MP/E 17.75$2.1$5.15
- IPSCCentury Therapeutics Inc. Common Stock$1.37▼ 8.67%Market cap $342.67MP/E —$0.435$3.04
- FATEFate Therapeutics Inc. Common Stock$1.79▼ 7.25%Market cap $290.23MP/E —$0.95$3.23
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| IKT Inhibikase Therapeutics Inc. Common Stock | $318.20M | — | $1.65 | ▼ 9.84% | $1.33$2.61 |
| AVXL Anavex Life Sciences Corp. Common Stock | $303.96M | — | $1.31 | ▼ 11.49% | $1.56$10.38 |
| NMRA Neumora Therapeutics Inc. Common Stock | $303.87M | — | $0.474 | ▲ 11.01% | $0.3154$3.65 |
| AGEN Agenus Inc. Common Stock | $335.19M | 3.19 | $6.04 | ▼ 9.58% | $2.71$10.31 |
| SABS SAB Biotherapeutics Inc. Common Stock | $294.39M | 17.75 | $2.53 | ▼ 2.32% | $2.1$5.15 |
| IPSC Century Therapeutics Inc. Common Stock | $342.67M | — | $1.37 | ▼ 8.67% | $0.435$3.04 |
| FATE Fate Therapeutics Inc. Common Stock | $290.23M | — | $1.79 | ▼ 7.25% | $0.95$3.23 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →- Dennis N. Berman · July 30, 2026 · Option Exercise21.9K @ $1.26
- RA CAPITAL MANAGEMENT, L.P. · July 29, 2026 · J18.03M
Institutional Ownership
March 31, 2026
- Total shares held
- 112.45M
- Total value held
- $188.53M
- Institutional holders
- 100
- Unknown13.02M
- Unknown10.88M
- Unknown8.63M
- Unknown8.06M
- Unknown6.61M
- Unknown6.30M
- Unknown5.94M
- Unknown5.85M
- Unknown5.40M
- Unknown4.45M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
Inhibikase Announces Nasdaq Inducement Grants
Inhibikase Therapeutics disclosed that it granted inducement awards under Nasdaq Listing Rule 5635(c)(4). This type of grant is typically used to attract or retain new employees without requiring a shareholder vote. The company's stock is currently trading near its 52-week low, with an average analyst target of $6.00.
Inhibikase Announces Nasdaq Inducement Grants. Inhibikase Therapeutics disclosed that it granted inducement awards under Nasdaq Listing Rule 5635(c)(4). This type of grant is typically used to attract or retain new employees without requiring a shareholder vote. The company's stock is currently trading near its 52-week low, with an average analyst target of $6.00.